FAQs about Cortrophin Gel

Cortrophin Gel was initially approved by the U.S. Food and Drug Administration (FDA) in 1954 to treat a number of inflammatory and autoimmune conditions; then in 1977 it was indicated for the management of acute MS relapses. The therapy fell out of use during the 1980s. The FDA approved the reintroduction of Cortrophin Gel in the U.S. market to treat MS relapses in late 2021.

In animal models, the use of Cortrophin Gel during pregnancy resulted in abnormalities with the developing fetus. A careful evaluation of the potential benefits and risks of treatment should be made when deciding whether or not to use Cortrophin Gel in patients who are pregnant, have the ability to become pregnant, or are breastfeeding. Babies born after being exposed to Cortrophin Gel during pregnancy should be monitored for signs of abnormal adrenal gland function.

The medication’s prescribing information does not report a direct interaction between Cortrophin Gel and alcohol. As alcohol can interfere with some medications and aggravate certain disease symptoms, patients are advised to talk to their healthcare provider about whether and how much it is safe for them to drink.

Everyone responds to medicines differently. Patients are encouraged to talk to their healthcare providers about what they should expect from their treatment given their unique situation.

Cortrophin Gel may result in the development of a hormonal imbalance called Cushingoid state, characterized by excess cortisol levels. Weight gain is a common symptom associated with Cushingoid state. Hair loss has not been reported as a side effect of Cortrophin Gel. Patients are advised to talk to their healthcare providers about any unanticipated effects from the medication.

Related Articles